These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 18037225

  • 1. Disease-modifying drugs and Parkinson's disease.
    Allain H, Bentué-Ferrer D, Akwa Y.
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotective and neurorestorative strategies for Parkinson's disease.
    Dawson TM, Dawson VL.
    Nat Neurosci; 2002 Nov; 5 Suppl():1058-61. PubMed ID: 12403986
    [Abstract] [Full Text] [Related]

  • 3. Drug Insight: new drugs in development for Parkinson's disease.
    Colosimo C, Fabbrini G, Berardelli A.
    Nat Clin Pract Neurol; 2006 Nov; 2(11):600-10. PubMed ID: 17057747
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME.
    J Neurosci Methods; 2004 Oct 30; 139(2):121-43. PubMed ID: 15488225
    [Abstract] [Full Text] [Related]

  • 5. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K.
    Ann Neurol; 2003 Oct 30; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G, Sesar A, Valldeoriola F, Compta Y, Herrero MT, Martínez Castrillo JC, López Lozano JJ, Bergaretxe A, Vela L, Fernández JM, Castro A, Kulisevski J, Lezcano E, Vaamonde J, López Del Val J, Chacón J, Vivancos F, Luquin R, Aguilar M, Burguera JA, Salvador C, Menéndez Guisasola L, Catalán MJ, Mir P, Campos V, Grandas F, Mínguez A, Balaguer E, Yáñez R, Leiva C, García Ruiz P, Cubo E.
    Neurologia; 2009 Mar 30; 24(2):113-24. PubMed ID: 19322690
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Disease modification in Parkinson's disease.
    Schapira AH.
    Lancet Neurol; 2004 Jun 30; 3(6):362-8. PubMed ID: 15157851
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW, Kieburtz K, Schapira AH.
    Ann Neurol; 2008 Dec 30; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [Abstract] [Full Text] [Related]

  • 16. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM, Ravina B.
    Semin Neurol; 2007 Apr 30; 27(2):106-12. PubMed ID: 17390255
    [Abstract] [Full Text] [Related]

  • 17. Current management of Parkinson's disease.
    Salawu F, Olokoba A, Danburam A.
    Ann Afr Med; 2010 Apr 30; 9(2):55-61. PubMed ID: 20587924
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
    Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL.
    Biochem Pharmacol; 2006 Nov 15; 72(10):1197-206. PubMed ID: 16901468
    [Abstract] [Full Text] [Related]

  • 20. Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation.
    Asanuma M, Miyazaki I.
    Expert Rev Neurother; 2006 Sep 15; 6(9):1313-25. PubMed ID: 17009919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.